Highlights Abeona Therapeutics Inc.

Equities

ABEO

US00289Y2063

Real-time Estimate Cboe BZX Other stock markets 02:33:05 2024-04-29 pm EDT			5-day change	1st Jan Change
3.49 ^USD	+7.06%		-52.79%	-30.64%

Apr. 23	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Apr. 23	Top Midday Decliners	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Abeona Therapeutics Shares Slump After Plans to Reapply for Pz-cel Drug Approval	Apr. 22	MT
Abeona Therapeutics Inc. Provides Regulatory Update on Pz-Cel	Apr. 22	CI
Abeona Therapeutics Shares Fall After 2023 Results, FDA Observations on Cleveland Facility	Mar. 18	MT
Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility	Mar. 18	DJ
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Abeona Says FDA Confirms Target Action Date For Pz-cel Application After Inspection	Feb. 01	MT
Abeona Therapeutics Inc. Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application	Nov. 27	CI
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Abeona Therapeutics Seeks FDA Priority Review for Potential Treatment of Recessive Dystrophic Epidermolysis Bullosa	23-09-26	MT
Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa	23-09-26	CI
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission	23-08-30	CI
Abeona Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Abeona Therapeutics Submits Briefing Package for US FDA Meeting on Skin Disorder Investigational Therapy	23-07-28	MT
Abeona Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Abeona Therapeutics Announces Additional Phase 3 Viital Study Results for Eb-101 Presented At the International Societies for Investigative Dermatology 2023 Meeting	23-05-11	CI
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Abeona Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Abeona Therapeutics Inc. Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results for Oral Presentation At International Societies for Investigative Dermatology 2023 Meeting	23-03-16	CI
Abeona Therapeutics Announces Update on AAV Ophthalmology Program	23-03-14	CI
Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Abeona Therapeutics Inc.

Equities

ABEO

US00289Y2063

Highlights

Filters